Eduardo Agüera

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease

Edmond Teng, Paul T. Manser, Karen Pickthorn et al. · JAMA Neurology · 2022 · 191 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Neuromyelitis optica spectrum disorders

María Sepúlveda, Thaís Armangué, Núria Solà‐Valls et al. · Neurology Neuroimmunology & Neuroinflammation · 2016 · 152 citations · Full text

Medicine, Neurology, Immunopathology +14

Peripheral oxidative stress in relapsing–remitting multiple sclerosis

Inmaculada Tasset, Eduardo Agüera, Fernando Sánchez‐López et al. · Clinical Biochemistry · 2012 · 122 citations

Life Sciences, Neurology, Neuroscience +14

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

Antonio Uccelli, Alice Laroni, Rehiana Ali et al. · The Lancet Neurology · 2021 · 109 citations

Life Sciences, Neurology, Neuroscience +15